BIIB Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Biogen (NASDAQ: BIIB)
›
Biogen (NASDAQ: BIIB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 7,500 employees.
The shares were at 247.13 USD on 19 November 2026, up 57.7% over 52 weeks. Its 52-week range is 151.83 USD to 261.00 USD: the price is 5.3% below the high and 62.8% above the low.
At a market capitalisation of 36.53B USD, it trades at 107.0 times trailing earnings and 15.2 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a premium of 311% for BIIB.
Biogen reports return on equity of 7.1%, an operating margin of 23.5% and revenue up 10.6% year over year.
Its debt exceeds its cash by 6.50B USD, a debt-to-equity ratio of 0.36. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 32 analysts cover the stock, with an average rating of Buy; their mean price target of 268.26 USD is 8.6% above the current price. The next earnings report is expected on 5 February 2027.